ERAS

In the past six months, Erasca's stock has been impacted by several events. Positive preliminary Phase 1 data for ERAS-0015 initially led to optimism, but the stock plummeted due to the disclosure of a patient death in the ERAS-0015 trial. Revolution Medicines accused Erasca of improperly comparing preclinical data, adding to investor scrutiny. Erasca completed an upsized public offering of 22.5 million shares, generating approximately $225 million. Erasca is scheduled to present at the Bank of America Securities Health Care Conference in May 2026. Analysts have maintained a "Moderate Buy" consensus rating, but there is disagreement regarding the stock's outlook.